PE43398A1 - Quinoxalinadionas - Google Patents
QuinoxalinadionasInfo
- Publication number
- PE43398A1 PE43398A1 PE1997000162A PE00016297A PE43398A1 PE 43398 A1 PE43398 A1 PE 43398A1 PE 1997000162 A PE1997000162 A PE 1997000162A PE 00016297 A PE00016297 A PE 00016297A PE 43398 A1 PE43398 A1 PE 43398A1
- Authority
- PE
- Peru
- Prior art keywords
- formula
- alkyl
- compounds
- piridinyl
- seizure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 abstract 2
- 230000000573 anti-seizure effect Effects 0.000 abstract 2
- -1 IMIDAZOLYL Chemical class 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- NOJNFULGOQGBKB-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[[4-(6-ethoxypyridin-3-yl)phenyl]methyl]-5-[(5-methylpyridin-2-yl)methoxy]indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C1=NC(OCC)=CC=C1C(C=C1)=CC=C1CN1C2=CC=C(OCC=3N=CC(C)=CC=3)C=C2C(SC(C)(C)C)=C1CC(C)(C)C([O-])=O NOJNFULGOQGBKB-UHFFFAOYSA-M 0.000 abstract 1
- 150000003536 tetrazoles Chemical group 0.000 abstract 1
- 150000003852 triazoles Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Luminescent Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
SE REFIEREN A LOS COMPUESTOS DE FORMULA (I) Y A LOS COMPUESTOS INTERMEDIOS DE FORMULA (II), EN DONDE: R ES TRIAZOL O TETRAZOL (CON 1 o 2 SUSTITUYENTES DE ALQUILO C1-C4, ALCOXI C1-C4, FENILO OPCIONALMENTE SUSTITUIDO o HET, ENTRE OTROS), O ES PIRIDINILO O PIRIMIDINILO; HET ES PIRIDINILO O IMIDAZOLILO, ENTRE OTROS, LOS CUALES SE ENCUENTRAN OPCIONALMENTE SUSTITUIDOS Y OPCIONALMENTE CONDENSADOS CON BENCENO; R1 Y R2 SON Cl o ALQUILO C1-C4, ENTRE OTROS; R5 Y R6 SON ALQUILO C1-C4, BENCILO OPCIONALMENTE SUSTITUIDO, O TOMADOS JUNTOS R5 Y R6 FORMAN ALQUILENO C1-C6, CH(FENILO), CH(4-METOXIFENILO) O CH(3,4-DIMETOXIFENILO); SIENDO EL COMPUESTO DE FORMULA (I) PREFERIDO LA SAL SODICA O LA BASE LIBRE R-(-)-6,7-DICLORO-5-[3-METOXIMETIL-5-(3-PIRIDINIL)-4H-1,2,4-TRIAZOL-4-IL]-2,3(1H,4H)-QUINOXALINADIONA. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE (I), QUE COMPRENDE LA HIDROLISIS ACIDA O BASICA DEL COMPUESTO DE FORMULA (II). LOS COMPUESTOS OBTENIDOS ACTUAN COMO ANTAGONISTAS SELECTIVOS DEL RECEPTOR N-METIL-D-ASPARTATO (NMDA), SIENDO UTILES EN EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS AGUDOS Y CRONICOS, COMO ANTICONVULSIVOS, ANSIOLITICOS, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
Publications (1)
Publication Number | Publication Date |
---|---|
PE43398A1 true PE43398A1 (es) | 1998-08-29 |
Family
ID=10790134
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1997000162A PE43398A1 (es) | 1996-03-09 | 1997-03-06 | Quinoxalinadionas |
PE1998000128A PE58199A1 (es) | 1996-03-09 | 1998-02-23 | Quinoxalinadionas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1998000128A PE58199A1 (es) | 1996-03-09 | 1998-02-23 | Quinoxalinadionas |
Country Status (42)
Country | Link |
---|---|
US (1) | US6376490B1 (es) |
EP (1) | EP0885212B1 (es) |
JP (1) | JP3110467B2 (es) |
KR (1) | KR100288099B1 (es) |
CN (1) | CN1103770C (es) |
AP (1) | AP767A (es) |
AR (1) | AR006119A1 (es) |
AT (1) | ATE208773T1 (es) |
AU (1) | AU717972B2 (es) |
BG (1) | BG63340B1 (es) |
BR (1) | BR9707851A (es) |
CA (1) | CA2248366C (es) |
CO (1) | CO4770976A1 (es) |
CZ (1) | CZ292792B6 (es) |
DE (1) | DE69708269T2 (es) |
DK (1) | DK0885212T3 (es) |
DZ (1) | DZ2188A1 (es) |
EA (1) | EA001730B1 (es) |
ES (1) | ES2163742T3 (es) |
GB (1) | GB9605027D0 (es) |
HN (1) | HN1998000034A (es) |
HR (1) | HRP970132A2 (es) |
HU (1) | HUP9900975A3 (es) |
ID (1) | ID18112A (es) |
IL (1) | IL125491A (es) |
IS (1) | IS4811A (es) |
MA (1) | MA26422A1 (es) |
NO (1) | NO984058L (es) |
NZ (1) | NZ331060A (es) |
OA (1) | OA10850A (es) |
PE (2) | PE43398A1 (es) |
PL (1) | PL329032A1 (es) |
PT (1) | PT885212E (es) |
SI (1) | SI0885212T1 (es) |
SK (1) | SK283467B6 (es) |
TN (1) | TNSN97044A1 (es) |
TR (1) | TR199801782T2 (es) |
TW (1) | TW454004B (es) |
UY (1) | UY24482A1 (es) |
WO (1) | WO1997032873A1 (es) |
YU (2) | YU39698A (es) |
ZA (1) | ZA971987B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9808126A (pt) * | 1997-02-27 | 2000-03-08 | Pfizer | Quinoxalinodionas |
AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
DE10005150A1 (de) | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
RU2002133666A (ru) * | 2000-05-19 | 2007-05-10 | Мерк Патент ГмбХ (DE) | Производные триазола |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
MY145368A (en) * | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
CN1926647B (zh) | 2004-02-06 | 2010-04-14 | 国立大学法人山口大学 | 储能装置用电极及其制造方法 |
JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
US8603980B2 (en) | 2007-01-16 | 2013-12-10 | The Johns Hopkins University | Glutamate receptor antagonists and methods of use |
EP2117540A1 (en) | 2007-03-01 | 2009-11-18 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
CN104370834B (zh) * | 2007-05-17 | 2017-04-19 | 株式会社半导体能源研究所 | 三唑衍生物 |
SG178953A1 (en) | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
JP2016507537A (ja) * | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 置換アセチレン誘導体およびmGluR4の正のアロステリックモジュレーターとしてのそれらの使用 |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1,3,4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0556393B1 (en) * | 1990-11-06 | 2000-07-26 | Yamanouchi Pharmaceutical Co. Ltd. | Fused pyrazine derivative |
DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
BR9808126A (pt) * | 1997-02-27 | 2000-03-08 | Pfizer | Quinoxalinodionas |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE43398A1 (es) | Quinoxalinadionas | |
KR880013909A (ko) | 고혈압 치료 화합물에 대한 테트라졸 중간체 | |
AP2001002307A0 (en) | B3 adrenergic receptor agonists and uses thereof. | |
MX9702601A (es) | AGONISTAS beta-ADRENERGICOS HETEROCICLICOS. | |
WO2000067735A3 (en) | USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION | |
TR200001079T2 (tr) | Bisiklik kinaz inhibitörleri. | |
PL361361A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
PE20070355A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion | |
NO20025640D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
DE2967005D1 (en) | 2-alkoxycarbonylamino benzimidazoles having a halogen-containing substituent, their preparation and their use as parasiticides | |
DK83684D0 (da) | Substituerede diazolylalkylcarbinoler, deres fremstilling og anvendelse som antimykotiske midler | |
WO2001036425A3 (de) | Imidazolverbindungen als phosphodiesterase vii-hemmer | |
ID23954A (id) | Tetrahidrogama-karbolin | |
PE20001456A1 (es) | Compuestos calcioliticos | |
ATE284871T1 (de) | Bicyclische vasopressin-agoniste | |
IL70718A0 (en) | Triazole derivatives,their preparation and pharmaceutical compositions containing them | |
PT1019048E (pt) | Uso de um antagonista do receptor da angiotensina ii para a preparacao de farmacos para aumentar a taxa de sobrevivencia de pacientes sujeitos a transplante renal | |
DE69221634D1 (de) | 5-Piperazinylalkyl)-1,5-Benzothiazepinone verwendbar als Calciumantagonisten | |
ES8504750A1 (es) | Un procedimiento para preparar compuestos heterociclicos | |
NZ309036A (en) | pyrazole or triazole - oxybenzyl alkoxyacrylic acid esters, process for producing them and their use as fungicides | |
CO5261532A1 (es) | Compuestos heterociclicos sililados, procedimiento para la preparacion de estos y composicion farmaceutica que los contiene | |
EA200100150A1 (ru) | Биспиперидины в качестве противотромботических агентов | |
RU2007146731A (ru) | Тромбин-ингибирующие производные 2-оксо-1, 2, 5, 6-тетрагидропиридина | |
PE20020732A1 (es) | Profarmacos de compuestos de azol solubles en agua | |
TH52364A (th) | ปรปักษ์ของตัวรับเบนซอกซาซิโนนโดพามีน d4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |